(PharmaNewsWire.Com, July 26, 2017 ) According to Publisher, the Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2%. Drivers that are shaping the global market include, growing incidences of chronic kidney diseases, rise in aged population, rising incidence of diabetes and obesity related disorders, significant unmet requirements and beneficial reimbursement policies. On the other hand, factors such as intense competition from biosimilars and growing preferences of generic drugs are creating a negative impact on the market growth.
By end user, the hospital segment is anticipated to dominate the market globally. North America leads the global market with a largest market share driven by huge acceptance of advanced technological products.
Regions Covered: -North America - US - Canada - Mexico -Europe - Germany - France - Italy - UK - Spain - Rest of Europe -Asia Pacific - Japan - China - India - Australia - New Zealand - Rest of Asia Pacific -Rest of the World - Middle East - Brazil - Argentina - South Africa - Egypt
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
